FOR IMMEDIATE RELEASE

PRESS RELEASE

CEO OF BIOPHARMA COMPANY UCB TO CHAIR IMI GOVERNING BOARD

Roch Doliveux confirms industry’s commitment to unique EU public-private partnership

BRUSSELS (Belgium), 7 March 2012 – The Innovative Medicines Initiative (IMI) announced today that Roch Doliveux, CEO of the biopharmaceutical company UCB, has been appointed Chairman of the Governing Board of IMI. IMI is a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). UCB has been involved in IMI since its initiation, and Roch Doliveux has been a member of the IMI Governing Board since May 2010.

IMI currently funds 30 projects with a combined budget of around €600 million and covering drug safety and efficacy, knowledge management, and education & training.

Michel Goldman, Executive Director of IMI said: ‘IMI will greatly benefit from the leadership and patient-centric perspective of Roch Doliveux. As Chair of the IMI Governing Board, Roch will be in a unique position to move forward his vision for the future of the pharmaceutical industry based on open innovation and precompetitive research. The early achievements of the ongoing IMI projects demonstrate that this new model based on public-private partnership is already successful.’

Roch Doliveux, CEO of UCB and member of the Board of the European Federation of Pharmaceutical Association (EFPIA) says: ‘The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs and bring safer, more efficacious and cost-effective treatments to patients. EFPIA considers IMI as a key instrument to implement the new business models which will ensure the sustainability of pharmaceutical industry and increase the well-being of patients across Europe.’

UCB is a significant contributor to IMI. UCB participates in 15 of the consortia within IMI, providing expert input on topics which include neurodegenerative disorders, inflammation, immunogenicity, predictive toxicology, pharmacovigilance, translational safety biomarkers, and strategies for treating COPD (Chronic Obstructive Pulmonary Disease), as well as a number of training programmes.

Note to editors

Roch Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB Group on January 1, 2005. He is a member of the Board of Directors of UCB, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), the Innovative Medicines Initiative Board, the Science & Business Innovation Board, and WELBIO (Walloon Institute for Life Lead Sciences). He is also a member of the INSEAD International Council and founder of the Caring Entrepreneurship Fund (King Baudouin Foundation). For a full biography, visit UCB’s website.

Press contacts

<table>
<thead>
<tr>
<th>Innovative Medicines Initiative</th>
<th>UCB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim De Rijck – External Relations Manager</td>
<td>Laurent Schots – Media Relations Manager</td>
</tr>
<tr>
<td>Tel: +32 484 89 62 27</td>
<td>Tel: +32 493 09 66</td>
</tr>
<tr>
<td><a href="mailto:kim.derijck@imi.europa.eu">kim.derijck@imi.europa.eu</a></td>
<td><a href="mailto:laurent.schots@ucb.com">laurent.schots@ucb.com</a></td>
</tr>
</tbody>
</table>

Press contact

Innovative Medicines Initiative (IMI) - Executive Office
kim.derijck@imi.europa.eu – www.imi.europa.eu – Tel: +32 (0)2-221 81 83
Postal mail: IMI JU, TO56, Office 6/3, 1049 Brussels
Visiting address: Ave de la Toison d’Or 56-60, 1060 Brussels, Belgium
ABOUT THE INNOVATIVE MEDICINES INITIATIVE (IMI):
IMI is the world’s largest public-private partnership in health research and development. Through the 7th Framework Programme for Research, the European Union contributes €1 billion to the IMI research programme, which is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is improving the environment for pharmaceutical innovation in Europe, by engaging and supporting networks of industrial and academic experts in collaborative research projects. The Innovative Medicines Initiative is currently funding 30 projects, many of which are already producing impressive results. A comprehensive overview of ongoing projects is available at www.imi.europa.eu.
IMI Governing Board: www.imi.europa.eu/content/governing-board

ABOUT UCB
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).
www.ucb.com
UCB press release: www.ucb.presscentre.com

ABOUT EFPIA:
EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 31 national associations and 35 leading pharmaceutical companies, EFPIA provides the voice of 2,000 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.